#United States #Precision Medicine #Carlsbad #Tyra Biosciences #Dabogratinib

Tyra Biosciences Reports Second Quarter 2026 Financial Results

Tyra Biosciences, Inc. (Nasdaq: TYRA), a biotechnology firm at the forefront of precision medicine, has publicly shared its financial results for the second quarter of 2026. The company is dedicated to developing innovative treatments targeting specific pathways, particularly focusing on Fibroblast Growth Factor Receptor (FGFR) biology. The latest data reveal both encouraging advancements in their clinical pipeline and financial performance.

Key Financial Highlights

As of June 30, 2026, Tyra has reported cash, cash equivalents, and marketable securities totaling $353.9 million, providing a solid foundation to pursue its clinical objectives through the latter half of 2028. The research and development expenses for this quarter reached $39.2 million, an increase from the $24.3 million recorded during the same period in 2025. This uptick is primarily attributed to ongoing clinical trials, especially those concerning the oral drug Dabogratinib.

Despite the positive trajectory, the company reported a net loss of $45.6 million for Q2 2026, compared to a $28.1 million loss in Q2 2025. This reflects increased investment in expanding their development initiatives, particularly in precision oncology and the treatment of skeletal dysplasia conditions.

Clinical Pipeline Updates

Tyra Biosciences is focusing on its three pivotal trials involving Dabogratinib, which is being evaluated as a selective treatment option for three significant conditions:
SURF302: Targeting intermediate-risk non-muscle invasive bladder cancer (IR NMIBC). Initial clinical data is expected to be released in September 2026, which will inform the efficacy and safety of the oral medication.
SURF303: A study investigating low-grade upper tract urothelial carcinoma, with initial results anticipated in 2027. This study is designed with a pivotal intent to support regulatory submissions.
* BEACH301: This study is focused on children aged 3 to 10 with achondroplasia, showcasing Tyra's commitment to pediatric healthcare. A preliminary report on safety findings from this cohort is expected at the end of Q1 2027.

Tyra’s dedication to advancing these clinical trials underscores the overarching goal of enhancing treatment experiences for patients living with conditions driven by FGFR3 pathways. Todd Harris, PhD, President and CEO of Tyra Biosciences, highlighted the urgency for alternatives, stating, "Patients with IR NMIBC often endure a lifelong cycle of recurrent disease, thus the necessity for more effective and convenient treatment options."

Leadership Changes and Strategies

In its pursuit to advance the treatment of skeletal dysplasia, Tyra appointed Jonathan Day as the Executive Vice President of Clinical Development. Dr. Day brings extensive experience from his previous roles, particularly his success with the drug vosoritide for achondroplasia. His expertise is expected to play a crucial role in steering Tyra’s programs for oral Dabogratinib forward.

The company also amended its Atthe-Market (ATM) sales agreement with TD Securities, enabling it to raise up to an additional $250 million through the sale of common stock. This strategic financial maneuver will facilitate continued investment in Tyra's extensive clinical pipeline.

Looking Ahead

As Tyra Biosciences continues to cultivate its innovative pipeline and strengthen its financial footing, the future appears bright. The upcoming clinical data and ongoing strategic initiatives will be critical as they aim to achieve commercialization across their pivotal indications. With groundbreaking candidates on the verge of pivotal trials, Tyra is well positioned to potentially change the landscape of treatment for FGFR-driven diseases.

In summary, Tyra Biosciences is making strides both financially and clinically, with significant updates projected in the months ahead. Investors and stakeholders remain hopeful, eager to see if the innovative therapies being developed will translate to successful outcomes for patients in need.